The easy book of cancer pharmacology /:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Biomedical,
[2016]
|
| Schriftenreihe: | Cancer etiology, diagnosis, and treatments.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | 1 online resource. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781634850438 1634850432 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1162314634 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 160307s2016 nyu ob 001 0 eng | ||
| 010 | |a 2020677742 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d VLY |d OCLCO |d N$T |d EBLCP |d OCLCF |d YDX |d AGLDB |d SNK |d DKU |d AUW |d INTCL |d MHW |d BTN |d IGB |d D6H |d VTS |d AU@ |d G3B |d SCB |d S8J |d S9I |d STF |d M8D |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 954215085 | ||
| 020 | |a 9781634850438 |q (ebook) | ||
| 020 | |a 1634850432 | ||
| 020 | |z 1634850386 | ||
| 020 | |z 9781634850384 | ||
| 035 | |a (OCoLC)1162314634 |z (OCoLC)954215085 | ||
| 050 | 0 | 0 | |a RC271.C5 |
| 060 | 4 | |a QZ 39 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 7 | |a 616.99/4061 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 4 | |a The easy book of cancer pharmacology / |c Esther Una Cidon, editor. |
| 246 | 3 | 0 | |a Cancer pharmacology |
| 264 | 1 | |a New York : |b Nova Biomedical, |c [2016] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Cancer Etiology, Diagnosis, and Treatments.; Pharmacology-Research, Safety Testing, and Regulation | |
| 490 | 1 | |a Nova Biomedical | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a THE EASY BOOK OF CANCER PHARMACOLOGY; THE EASY BOOK OF CANCER PHARMACOLOGY; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; PREFACE; Chapter 1: ABIRATERONE: ABIRATERONE ACETATE: CB7630: ZYTIGA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2]; Mechanism of Resistance; Indications [2]; Dosages; Methods of Preparation/Administration; Special Information and Cautions [2]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; Immunisations; Warnings [2] | |
| 505 | 8 | |a Mineralocorticoid ExcessAdrenocortical Insufficiency; Hepatotoxicity; Food Effect; Toxicities [2]; Dose Modifications [2]; Interactions [2]; CONCLUSION; REFERENCES; Chapter 2: ALBUMIN-BOUND (NAB) PACLITAXEL, ABRAXANE® ; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; Pharmacokinetics; INDICATIONS; Metastatic Breast Cancer; Metastatic Pancreatic Adenocarcinoma; Dosages; METHODS OF PREPARATION/ADMINISTRATION; SPECIAL INFORMATION AND CAUTIONS; Contraindications; Elderly; Pediatric; Renal; Hepatic; Immunisations; Pregnancy; Breast-Feeding | |
| 505 | 8 | |a TOXICITIES [9, 10]Dose Modifications; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 3: AFLIBERCEPT. ZALTRAP®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; MECHANISM OF RESISTANCE; PHARMACOKINETICS [6]; INDICATIONS; DOSAGES; METHODS OF PREPARATION/ADMINISTRATION [6]; SPECIAL INFORMATION AND CAUTIONS [6]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; WARNINGS [6]; Hemorrhage; Gastrointestinal Perforation; Compromised Wound Healing; Fistula Formation; Hypertension; Arterial Thromboembolic Events | |
| 505 | 8 | |a ProteinuriaNeutropenic Complications; Diarrhea and Dehydration; Pregnancy and Nursing; Immunisations; TOXICITIES; DOSE MODIFICATIONS; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 4: AXITINIB. INLYTA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2, 3]; Mechanism of Resistance [3]; Indications; Dosage; Methods of Preparation/Administration [1]; Special Information and Cautions [1]; Contraindications; Elderly; Pediatric; Renal Impairment; Hepatic Impairment; Breast-Feeding; Pregnancy; Immunisations; Warnings [1]; Hypertension | |
| 505 | 8 | |a Thromboembolic EventsHemorrhagic Events; Toxicities [1]; Dose Modifications [1]; Hepatic Impairment; Concomitant Strong CYP3A4/5 Inhibitors; Concomitant Strong CYP3A4/5 Inducers; Interactions [1]; CYP3A4/5 Inhibitors; CYP1A2 and CYP2C19 Inhibitors; CYP3A4/5 Inducers; CONCLUSION; REFERENCES; Chapter 5: BEVACIZUMAB. AVASTIN®; ABSTRACT; INTRODUCTION; DRUG CLASSIFICATION; MECHANISM OF ACTION; PHARMACOKINETICS; MECHANISM OF RESISTANCE; INDICATIONS [10]; DOSAGES [10] ; METHODS OF ADMINISTRATION/PREPARATION [10]; SPECIAL INFORMATION AND CAUTIONS [10]; Contraindications; Elderly Patients | |
| 650 | 0 | |a Cancer |x Chemotherapy. |0 http://id.loc.gov/authorities/subjects/sh85019497 | |
| 650 | 0 | |a Clinical pharmacology. |0 http://id.loc.gov/authorities/subjects/sh90000174 | |
| 650 | 0 | |a Pharmacology. |0 http://id.loc.gov/authorities/subjects/sh85100599 | |
| 650 | 2 | |a Antineoplastic Agents |x pharmacology |0 https://id.nlm.nih.gov/mesh/D000970Q000494 | |
| 650 | 2 | |a Pharmacology, Clinical |0 https://id.nlm.nih.gov/mesh/D010601 | |
| 650 | 2 | |a Pharmacology |0 https://id.nlm.nih.gov/mesh/D010600 | |
| 650 | 6 | |a Cancer |x Chimiothérapie. | |
| 650 | 6 | |a Pharmacologie clinique. | |
| 650 | 6 | |a Pharmacologie. | |
| 650 | 7 | |a pharmacology. |2 aat | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Clinical Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Diseases |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Evidence-Based Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Internal Medicine |2 bisacsh | |
| 650 | 7 | |a Pharmacology |2 fast | |
| 650 | 7 | |a Clinical pharmacology |2 fast | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast | |
| 650 | 7 | |a Antineoplastic agents |2 fast | |
| 655 | 7 | |a Handbooks and manuals |2 fast | |
| 700 | 1 | |a Cidon, Esther Una, |e editor. |0 http://id.loc.gov/authorities/names/n2017055084 | |
| 758 | |i has work: |a The easy book of cancer pharmacology (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFTcyJdYV7dPHycPXdk8VK |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t The easy book of cancer pharmacology |d New York : Nova Biomedical, [2016] |z 9781634850384 |w (DLC) 2016935307 |
| 830 | 0 | |a Cancer etiology, diagnosis, and treatments. |0 http://id.loc.gov/authorities/names/n2009183163 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1292490 |3 Volltext |
| 938 | |a YBP Library Services |b YANK |n 12933030 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL4689736 | ||
| 938 | |a EBSCOhost |b EBSC |n 1292490 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1162314634 |
|---|---|
| _version_ | 1816882522711130112 |
| adam_text | |
| any_adam_object | |
| author2 | Cidon, Esther Una |
| author2_role | edt |
| author2_variant | e u c eu euc |
| author_GND | http://id.loc.gov/authorities/names/n2017055084 |
| author_facet | Cidon, Esther Una |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 |
| callnumber-search | RC271.C5 |
| callnumber-sort | RC 3271 C5 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | THE EASY BOOK OF CANCER PHARMACOLOGY; THE EASY BOOK OF CANCER PHARMACOLOGY; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; PREFACE; Chapter 1: ABIRATERONE: ABIRATERONE ACETATE: CB7630: ZYTIGA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2]; Mechanism of Resistance; Indications [2]; Dosages; Methods of Preparation/Administration; Special Information and Cautions [2]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; Immunisations; Warnings [2] Mineralocorticoid ExcessAdrenocortical Insufficiency; Hepatotoxicity; Food Effect; Toxicities [2]; Dose Modifications [2]; Interactions [2]; CONCLUSION; REFERENCES; Chapter 2: ALBUMIN-BOUND (NAB) PACLITAXEL, ABRAXANE® ; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; Pharmacokinetics; INDICATIONS; Metastatic Breast Cancer; Metastatic Pancreatic Adenocarcinoma; Dosages; METHODS OF PREPARATION/ADMINISTRATION; SPECIAL INFORMATION AND CAUTIONS; Contraindications; Elderly; Pediatric; Renal; Hepatic; Immunisations; Pregnancy; Breast-Feeding TOXICITIES [9, 10]Dose Modifications; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 3: AFLIBERCEPT. ZALTRAP®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; MECHANISM OF RESISTANCE; PHARMACOKINETICS [6]; INDICATIONS; DOSAGES; METHODS OF PREPARATION/ADMINISTRATION [6]; SPECIAL INFORMATION AND CAUTIONS [6]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; WARNINGS [6]; Hemorrhage; Gastrointestinal Perforation; Compromised Wound Healing; Fistula Formation; Hypertension; Arterial Thromboembolic Events ProteinuriaNeutropenic Complications; Diarrhea and Dehydration; Pregnancy and Nursing; Immunisations; TOXICITIES; DOSE MODIFICATIONS; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 4: AXITINIB. INLYTA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2, 3]; Mechanism of Resistance [3]; Indications; Dosage; Methods of Preparation/Administration [1]; Special Information and Cautions [1]; Contraindications; Elderly; Pediatric; Renal Impairment; Hepatic Impairment; Breast-Feeding; Pregnancy; Immunisations; Warnings [1]; Hypertension Thromboembolic EventsHemorrhagic Events; Toxicities [1]; Dose Modifications [1]; Hepatic Impairment; Concomitant Strong CYP3A4/5 Inhibitors; Concomitant Strong CYP3A4/5 Inducers; Interactions [1]; CYP3A4/5 Inhibitors; CYP1A2 and CYP2C19 Inhibitors; CYP3A4/5 Inducers; CONCLUSION; REFERENCES; Chapter 5: BEVACIZUMAB. AVASTIN®; ABSTRACT; INTRODUCTION; DRUG CLASSIFICATION; MECHANISM OF ACTION; PHARMACOKINETICS; MECHANISM OF RESISTANCE; INDICATIONS [10]; DOSAGES [10] ; METHODS OF ADMINISTRATION/PREPARATION [10]; SPECIAL INFORMATION AND CAUTIONS [10]; Contraindications; Elderly Patients |
| ctrlnum | (OCoLC)1162314634 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06398cam a2200829 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1162314634</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">160307s2016 nyu ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2020677742</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">DLC</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCF</subfield><subfield code="d">YDX</subfield><subfield code="d">AGLDB</subfield><subfield code="d">SNK</subfield><subfield code="d">DKU</subfield><subfield code="d">AUW</subfield><subfield code="d">INTCL</subfield><subfield code="d">MHW</subfield><subfield code="d">BTN</subfield><subfield code="d">IGB</subfield><subfield code="d">D6H</subfield><subfield code="d">VTS</subfield><subfield code="d">AU@</subfield><subfield code="d">G3B</subfield><subfield code="d">SCB</subfield><subfield code="d">S8J</subfield><subfield code="d">S9I</subfield><subfield code="d">STF</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">954215085</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634850438</subfield><subfield code="q">(ebook)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1634850432</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1634850386</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781634850384</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1162314634</subfield><subfield code="z">(OCoLC)954215085</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RC271.C5</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QZ 39</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="4"><subfield code="a">The easy book of cancer pharmacology /</subfield><subfield code="c">Esther Una Cidon, editor.</subfield></datafield><datafield tag="246" ind1="3" ind2="0"><subfield code="a">Cancer pharmacology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Biomedical,</subfield><subfield code="c">[2016]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Cancer Etiology, Diagnosis, and Treatments.; Pharmacology-Research, Safety Testing, and Regulation</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Nova Biomedical</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">THE EASY BOOK OF CANCER PHARMACOLOGY; THE EASY BOOK OF CANCER PHARMACOLOGY; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; PREFACE; Chapter 1: ABIRATERONE: ABIRATERONE ACETATE: CB7630: ZYTIGA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2]; Mechanism of Resistance; Indications [2]; Dosages; Methods of Preparation/Administration; Special Information and Cautions [2]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; Immunisations; Warnings [2]</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Mineralocorticoid ExcessAdrenocortical Insufficiency; Hepatotoxicity; Food Effect; Toxicities [2]; Dose Modifications [2]; Interactions [2]; CONCLUSION; REFERENCES; Chapter 2: ALBUMIN-BOUND (NAB) PACLITAXEL, ABRAXANE® ; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; Pharmacokinetics; INDICATIONS; Metastatic Breast Cancer; Metastatic Pancreatic Adenocarcinoma; Dosages; METHODS OF PREPARATION/ADMINISTRATION; SPECIAL INFORMATION AND CAUTIONS; Contraindications; Elderly; Pediatric; Renal; Hepatic; Immunisations; Pregnancy; Breast-Feeding</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">TOXICITIES [9, 10]Dose Modifications; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 3: AFLIBERCEPT. ZALTRAP®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; MECHANISM OF RESISTANCE; PHARMACOKINETICS [6]; INDICATIONS; DOSAGES; METHODS OF PREPARATION/ADMINISTRATION [6]; SPECIAL INFORMATION AND CAUTIONS [6]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; WARNINGS [6]; Hemorrhage; Gastrointestinal Perforation; Compromised Wound Healing; Fistula Formation; Hypertension; Arterial Thromboembolic Events</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ProteinuriaNeutropenic Complications; Diarrhea and Dehydration; Pregnancy and Nursing; Immunisations; TOXICITIES; DOSE MODIFICATIONS; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 4: AXITINIB. INLYTA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2, 3]; Mechanism of Resistance [3]; Indications; Dosage; Methods of Preparation/Administration [1]; Special Information and Cautions [1]; Contraindications; Elderly; Pediatric; Renal Impairment; Hepatic Impairment; Breast-Feeding; Pregnancy; Immunisations; Warnings [1]; Hypertension</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Thromboembolic EventsHemorrhagic Events; Toxicities [1]; Dose Modifications [1]; Hepatic Impairment; Concomitant Strong CYP3A4/5 Inhibitors; Concomitant Strong CYP3A4/5 Inducers; Interactions [1]; CYP3A4/5 Inhibitors; CYP1A2 and CYP2C19 Inhibitors; CYP3A4/5 Inducers; CONCLUSION; REFERENCES; Chapter 5: BEVACIZUMAB. AVASTIN®; ABSTRACT; INTRODUCTION; DRUG CLASSIFICATION; MECHANISM OF ACTION; PHARMACOKINETICS; MECHANISM OF RESISTANCE; INDICATIONS [10]; DOSAGES [10] ; METHODS OF ADMINISTRATION/PREPARATION [10]; SPECIAL INFORMATION AND CAUTIONS [10]; Contraindications; Elderly Patients</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85019497</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical pharmacology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh90000174</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85100599</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">pharmacology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000970Q000494</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Pharmacology, Clinical</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D010601</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Pharmacology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D010600</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cancer</subfield><subfield code="x">Chimiothérapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pharmacologie clinique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pharmacologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">pharmacology.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Evidence-Based Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Internal Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical pharmacology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antineoplastic agents</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Handbooks and manuals</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cidon, Esther Una,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2017055084</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">The easy book of cancer pharmacology (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFTcyJdYV7dPHycPXdk8VK</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">The easy book of cancer pharmacology</subfield><subfield code="d">New York : Nova Biomedical, [2016]</subfield><subfield code="z">9781634850384</subfield><subfield code="w">(DLC) 2016935307</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Cancer etiology, diagnosis, and treatments.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2009183163</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1292490</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12933030</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL4689736</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1292490</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Handbooks and manuals fast |
| genre_facet | Handbooks and manuals |
| id | ZDB-4-EBA-on1162314634 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:29:57Z |
| institution | BVB |
| isbn | 9781634850438 1634850432 |
| language | English |
| lccn | 2020677742 |
| oclc_num | 1162314634 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource. |
| psigel | ZDB-4-EBA |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Nova Biomedical, |
| record_format | marc |
| series | Cancer etiology, diagnosis, and treatments. |
| series2 | Cancer Etiology, Diagnosis, and Treatments.; Pharmacology-Research, Safety Testing, and Regulation Nova Biomedical |
| spelling | The easy book of cancer pharmacology / Esther Una Cidon, editor. Cancer pharmacology New York : Nova Biomedical, [2016] 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier Cancer Etiology, Diagnosis, and Treatments.; Pharmacology-Research, Safety Testing, and Regulation Nova Biomedical Includes bibliographical references and index. THE EASY BOOK OF CANCER PHARMACOLOGY; THE EASY BOOK OF CANCER PHARMACOLOGY; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; PREFACE; Chapter 1: ABIRATERONE: ABIRATERONE ACETATE: CB7630: ZYTIGA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2]; Mechanism of Resistance; Indications [2]; Dosages; Methods of Preparation/Administration; Special Information and Cautions [2]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; Immunisations; Warnings [2] Mineralocorticoid ExcessAdrenocortical Insufficiency; Hepatotoxicity; Food Effect; Toxicities [2]; Dose Modifications [2]; Interactions [2]; CONCLUSION; REFERENCES; Chapter 2: ALBUMIN-BOUND (NAB) PACLITAXEL, ABRAXANE® ; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; Pharmacokinetics; INDICATIONS; Metastatic Breast Cancer; Metastatic Pancreatic Adenocarcinoma; Dosages; METHODS OF PREPARATION/ADMINISTRATION; SPECIAL INFORMATION AND CAUTIONS; Contraindications; Elderly; Pediatric; Renal; Hepatic; Immunisations; Pregnancy; Breast-Feeding TOXICITIES [9, 10]Dose Modifications; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 3: AFLIBERCEPT. ZALTRAP®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; MECHANISM OF RESISTANCE; PHARMACOKINETICS [6]; INDICATIONS; DOSAGES; METHODS OF PREPARATION/ADMINISTRATION [6]; SPECIAL INFORMATION AND CAUTIONS [6]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; WARNINGS [6]; Hemorrhage; Gastrointestinal Perforation; Compromised Wound Healing; Fistula Formation; Hypertension; Arterial Thromboembolic Events ProteinuriaNeutropenic Complications; Diarrhea and Dehydration; Pregnancy and Nursing; Immunisations; TOXICITIES; DOSE MODIFICATIONS; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 4: AXITINIB. INLYTA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2, 3]; Mechanism of Resistance [3]; Indications; Dosage; Methods of Preparation/Administration [1]; Special Information and Cautions [1]; Contraindications; Elderly; Pediatric; Renal Impairment; Hepatic Impairment; Breast-Feeding; Pregnancy; Immunisations; Warnings [1]; Hypertension Thromboembolic EventsHemorrhagic Events; Toxicities [1]; Dose Modifications [1]; Hepatic Impairment; Concomitant Strong CYP3A4/5 Inhibitors; Concomitant Strong CYP3A4/5 Inducers; Interactions [1]; CYP3A4/5 Inhibitors; CYP1A2 and CYP2C19 Inhibitors; CYP3A4/5 Inducers; CONCLUSION; REFERENCES; Chapter 5: BEVACIZUMAB. AVASTIN®; ABSTRACT; INTRODUCTION; DRUG CLASSIFICATION; MECHANISM OF ACTION; PHARMACOKINETICS; MECHANISM OF RESISTANCE; INDICATIONS [10]; DOSAGES [10] ; METHODS OF ADMINISTRATION/PREPARATION [10]; SPECIAL INFORMATION AND CAUTIONS [10]; Contraindications; Elderly Patients Cancer Chemotherapy. http://id.loc.gov/authorities/subjects/sh85019497 Clinical pharmacology. http://id.loc.gov/authorities/subjects/sh90000174 Pharmacology. http://id.loc.gov/authorities/subjects/sh85100599 Antineoplastic Agents pharmacology https://id.nlm.nih.gov/mesh/D000970Q000494 Pharmacology, Clinical https://id.nlm.nih.gov/mesh/D010601 Pharmacology https://id.nlm.nih.gov/mesh/D010600 Cancer Chimiothérapie. Pharmacologie clinique. Pharmacologie. pharmacology. aat HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Pharmacology fast Clinical pharmacology fast Cancer Chemotherapy fast Antineoplastic agents fast Handbooks and manuals fast Cidon, Esther Una, editor. http://id.loc.gov/authorities/names/n2017055084 has work: The easy book of cancer pharmacology (Text) https://id.oclc.org/worldcat/entity/E39PCFTcyJdYV7dPHycPXdk8VK https://id.oclc.org/worldcat/ontology/hasWork Print version: The easy book of cancer pharmacology New York : Nova Biomedical, [2016] 9781634850384 (DLC) 2016935307 Cancer etiology, diagnosis, and treatments. http://id.loc.gov/authorities/names/n2009183163 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1292490 Volltext |
| spellingShingle | The easy book of cancer pharmacology / Cancer etiology, diagnosis, and treatments. THE EASY BOOK OF CANCER PHARMACOLOGY; THE EASY BOOK OF CANCER PHARMACOLOGY; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; PREFACE; Chapter 1: ABIRATERONE: ABIRATERONE ACETATE: CB7630: ZYTIGA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2]; Mechanism of Resistance; Indications [2]; Dosages; Methods of Preparation/Administration; Special Information and Cautions [2]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; Immunisations; Warnings [2] Mineralocorticoid ExcessAdrenocortical Insufficiency; Hepatotoxicity; Food Effect; Toxicities [2]; Dose Modifications [2]; Interactions [2]; CONCLUSION; REFERENCES; Chapter 2: ALBUMIN-BOUND (NAB) PACLITAXEL, ABRAXANE® ; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; Pharmacokinetics; INDICATIONS; Metastatic Breast Cancer; Metastatic Pancreatic Adenocarcinoma; Dosages; METHODS OF PREPARATION/ADMINISTRATION; SPECIAL INFORMATION AND CAUTIONS; Contraindications; Elderly; Pediatric; Renal; Hepatic; Immunisations; Pregnancy; Breast-Feeding TOXICITIES [9, 10]Dose Modifications; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 3: AFLIBERCEPT. ZALTRAP®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; MECHANISM OF ACTION; MECHANISM OF RESISTANCE; PHARMACOKINETICS [6]; INDICATIONS; DOSAGES; METHODS OF PREPARATION/ADMINISTRATION [6]; SPECIAL INFORMATION AND CAUTIONS [6]; Contraindications; Elderly Patients; Pediatric Patients; Renal Impairment; Hepatic Impairment; WARNINGS [6]; Hemorrhage; Gastrointestinal Perforation; Compromised Wound Healing; Fistula Formation; Hypertension; Arterial Thromboembolic Events ProteinuriaNeutropenic Complications; Diarrhea and Dehydration; Pregnancy and Nursing; Immunisations; TOXICITIES; DOSE MODIFICATIONS; INTERACTIONS; CONCLUSION; REFERENCES; Chapter 4: AXITINIB. INLYTA®; ABSTRACT; INTRODUCTION; CLINICAL PHARMACOLOGY; Drug Classification; Mechanism of Action; Pharmacokinetics [2, 3]; Mechanism of Resistance [3]; Indications; Dosage; Methods of Preparation/Administration [1]; Special Information and Cautions [1]; Contraindications; Elderly; Pediatric; Renal Impairment; Hepatic Impairment; Breast-Feeding; Pregnancy; Immunisations; Warnings [1]; Hypertension Thromboembolic EventsHemorrhagic Events; Toxicities [1]; Dose Modifications [1]; Hepatic Impairment; Concomitant Strong CYP3A4/5 Inhibitors; Concomitant Strong CYP3A4/5 Inducers; Interactions [1]; CYP3A4/5 Inhibitors; CYP1A2 and CYP2C19 Inhibitors; CYP3A4/5 Inducers; CONCLUSION; REFERENCES; Chapter 5: BEVACIZUMAB. AVASTIN®; ABSTRACT; INTRODUCTION; DRUG CLASSIFICATION; MECHANISM OF ACTION; PHARMACOKINETICS; MECHANISM OF RESISTANCE; INDICATIONS [10]; DOSAGES [10] ; METHODS OF ADMINISTRATION/PREPARATION [10]; SPECIAL INFORMATION AND CAUTIONS [10]; Contraindications; Elderly Patients Cancer Chemotherapy. http://id.loc.gov/authorities/subjects/sh85019497 Clinical pharmacology. http://id.loc.gov/authorities/subjects/sh90000174 Pharmacology. http://id.loc.gov/authorities/subjects/sh85100599 Antineoplastic Agents pharmacology https://id.nlm.nih.gov/mesh/D000970Q000494 Pharmacology, Clinical https://id.nlm.nih.gov/mesh/D010601 Pharmacology https://id.nlm.nih.gov/mesh/D010600 Cancer Chimiothérapie. Pharmacologie clinique. Pharmacologie. pharmacology. aat HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Pharmacology fast Clinical pharmacology fast Cancer Chemotherapy fast Antineoplastic agents fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85019497 http://id.loc.gov/authorities/subjects/sh90000174 http://id.loc.gov/authorities/subjects/sh85100599 https://id.nlm.nih.gov/mesh/D000970Q000494 https://id.nlm.nih.gov/mesh/D010601 https://id.nlm.nih.gov/mesh/D010600 |
| title | The easy book of cancer pharmacology / |
| title_alt | Cancer pharmacology |
| title_auth | The easy book of cancer pharmacology / |
| title_exact_search | The easy book of cancer pharmacology / |
| title_full | The easy book of cancer pharmacology / Esther Una Cidon, editor. |
| title_fullStr | The easy book of cancer pharmacology / Esther Una Cidon, editor. |
| title_full_unstemmed | The easy book of cancer pharmacology / Esther Una Cidon, editor. |
| title_short | The easy book of cancer pharmacology / |
| title_sort | easy book of cancer pharmacology |
| topic | Cancer Chemotherapy. http://id.loc.gov/authorities/subjects/sh85019497 Clinical pharmacology. http://id.loc.gov/authorities/subjects/sh90000174 Pharmacology. http://id.loc.gov/authorities/subjects/sh85100599 Antineoplastic Agents pharmacology https://id.nlm.nih.gov/mesh/D000970Q000494 Pharmacology, Clinical https://id.nlm.nih.gov/mesh/D010601 Pharmacology https://id.nlm.nih.gov/mesh/D010600 Cancer Chimiothérapie. Pharmacologie clinique. Pharmacologie. pharmacology. aat HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Pharmacology fast Clinical pharmacology fast Cancer Chemotherapy fast Antineoplastic agents fast |
| topic_facet | Cancer Chemotherapy. Clinical pharmacology. Pharmacology. Antineoplastic Agents pharmacology Pharmacology, Clinical Pharmacology Cancer Chimiothérapie. Pharmacologie clinique. Pharmacologie. pharmacology. HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine Clinical pharmacology Cancer Chemotherapy Antineoplastic agents Handbooks and manuals |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1292490 |
| work_keys_str_mv | AT cidonestheruna theeasybookofcancerpharmacology AT cidonestheruna cancerpharmacology AT cidonestheruna easybookofcancerpharmacology |